{"protocolSection": {"identificationModule": {"nctId": "NCT00316082", "orgStudyIdInfo": {"id": "CV181-038"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise", "officialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-06"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-04-18", "studyFirstSubmitQcDate": "2006-04-19", "studyFirstPostDateStruct": {"date": "2006-04-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-08-17", "resultsFirstSubmitQcDate": "2009-08-17", "resultsFirstPostDateStruct": {"date": "2009-09-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-08", "lastUpdatePostDateStruct": {"date": "2015-04-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise", "detailedDescription": "All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive metformin (rescue medication) added onto their blinded study medication"}, "conditionsModule": {"conditions": ["Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 365, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin 2.5 mg QAM (A)", "type": "EXPERIMENTAL", "description": "PLUS open-label metformin (as needed as rescue medication)", "interventionNames": ["Drug: Saxagliptin", "Drug: metformin"]}, {"label": "Saxagliptin 2.5 mg titrated to 5 mg QAM (B)", "type": "EXPERIMENTAL", "description": "PLUS open-label metformin (as needed as rescue medication)", "interventionNames": ["Drug: Saxagliptin", "Drug: metformin"]}, {"label": "Saxagliptin 5 mg QAM (C)", "type": "EXPERIMENTAL", "description": "PLUS open-label metformin (as needed as rescue medication)", "interventionNames": ["Drug: Saxagliptin", "Drug: metformin"]}, {"label": "Saxagliptin 5 mg QPM (D)", "type": "EXPERIMENTAL", "description": "PLUS open-label metformin (as needed as rescue medication)", "interventionNames": ["Drug: Saxagliptin", "Drug: metformin"]}, {"label": "Placebo (E)", "type": "PLACEBO_COMPARATOR", "description": "PLUS open-label metformin (as needed as rescue medication)", "interventionNames": ["Drug: Placebo", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)", "armGroupLabels": ["Saxagliptin 2.5 mg QAM (A)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)", "armGroupLabels": ["Saxagliptin 2.5 mg titrated to 5 mg QAM (B)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)", "armGroupLabels": ["Saxagliptin 5 mg QAM (C)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)", "armGroupLabels": ["Saxagliptin 5 mg QPM (D)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Placebo", "description": "Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)", "armGroupLabels": ["Placebo (E)"]}, {"type": "DRUG", "name": "metformin", "description": "Tablets, Oral, 500-2000 mg, as needed (12 months LT)", "armGroupLabels": ["Placebo (E)", "Saxagliptin 2.5 mg QAM (A)", "Saxagliptin 2.5 mg titrated to 5 mg QAM (B)", "Saxagliptin 5 mg QAM (C)", "Saxagliptin 5 mg QPM (D)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1 (A1C) at Week 24", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Mean change from baseline in FPG at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Participants Achieving A1C < 7% at Week 24", "description": "Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24.", "timeFrame": "Week 24"}, {"measure": "Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24", "description": "Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes\n* Inadequate blood sugar control\n\nExclusion Criteria:\n\n* Previous treatment for diabetes\n* Current treatment with other medications to lower blood sugar\n* Major heart, liver or kidney problems\n* Women who are pregnant or breastfeeding", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "77 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Tomac, Inc.", "city": "Columbiana", "state": "Alabama", "zip": "35051", "country": "United States", "geoPoint": {"lat": 33.17817, "lon": -86.60721}}, {"facility": "Winston Technology, Inc.", "city": "Haleyville", "state": "Alabama", "zip": "35565", "country": "United States", "geoPoint": {"lat": 34.22649, "lon": -87.62141}}, {"facility": "Clinical Reseacrh Advantage/ Brown Family Medicine", "city": "Mesa", "state": "Arizona", "zip": "85213", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"facility": "Strategos Medical Group", "city": "Bakersfield", "state": "California", "zip": "93311", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Providence Clinical Research", "city": "Burbank", "state": "California", "zip": "91505", "country": "United States", "geoPoint": {"lat": 34.18084, "lon": -118.30897}}, {"facility": "Rx For Life, Inc", "city": "Cudahy", "state": "California", "zip": "90201", "country": "United States", "geoPoint": {"lat": 33.96057, "lon": -118.18535}}, {"facility": "Medical Group Of Encino", "city": "Encino", "state": "California", "zip": "91436", "country": "United States", "geoPoint": {"lat": 34.15917, "lon": -118.50119}}, {"facility": "Southland Clinical Research Center, Inc.", "city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Valley Research", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Diabetes Medical Center Of California", "city": "Northridge", "state": "California", "zip": "91325", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "In Private Prictice Clinic", "city": "Pico Rivera", "state": "California", "zip": "90660", "country": "United States", "geoPoint": {"lat": 33.98307, "lon": -118.09673}}, {"facility": "San Jose Clinical Research, Inc.", "city": "San Jose", "state": "California", "zip": "95128", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Central Florida Clinical Trials, Inc.", "city": "Altamonte Springs", "state": "Florida", "zip": "32714", "country": "United States", "geoPoint": {"lat": 28.66111, "lon": -81.36562}}, {"facility": "Accelovance", "city": "Melbourne", "state": "Florida", "zip": "32935", "country": "United States", "geoPoint": {"lat": 28.08363, "lon": -80.60811}}, {"facility": "University Family Healthcare, Pa", "city": "Sarasota", "state": "Florida", "zip": "34243", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Premier Healthcare", "city": "St. Petersburg", "state": "Florida", "zip": "33707", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Pinnacle Medical Research", "city": "Overland Park", "state": "Kansas", "zip": "66215", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Kansas City University Of Medicine And Biosciences", "city": "Kansas City", "state": "Missouri", "zip": "64106", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Primary Care Physicians, Pc", "city": "Wentzville", "state": "Missouri", "zip": "63385", "country": "United States", "geoPoint": {"lat": 38.81144, "lon": -90.85291}}, {"facility": "Physicians Research Center", "city": "Toms River", "state": "New Jersey", "zip": "08755", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Hudson Valley Clinical Research Center", "city": "Kingston", "state": "New York", "zip": "12401", "country": "United States", "geoPoint": {"lat": 41.92704, "lon": -73.99736}}, {"facility": "Neem Research Group Of Charlotte", "city": "Charlotte", "state": "North Carolina", "zip": "28262", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Diabetes Center- East Carolina University", "city": "Greenville", "state": "North Carolina", "zip": "27834", "country": "United States", "geoPoint": {"lat": 35.61266, "lon": -77.36635}}, {"facility": "Crescent Medical Research", "city": "Salisbury", "state": "North Carolina", "zip": "28144", "country": "United States", "geoPoint": {"lat": 35.67097, "lon": -80.47423}}, {"facility": "Community Health Care, Inc.", "city": "Barberton", "state": "Ohio", "zip": "44203", "country": "United States", "geoPoint": {"lat": 41.01283, "lon": -81.60512}}, {"facility": "Clinical Research Limited", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Wells Institute For Health Awareness", "city": "Kettering", "state": "Ohio", "zip": "45429", "country": "United States", "geoPoint": {"lat": 39.6895, "lon": -84.16883}}, {"facility": "Clinical Research Source, Inc", "city": "Perrysburg", "state": "Ohio", "zip": "43551", "country": "United States", "geoPoint": {"lat": 41.557, "lon": -83.62716}}, {"facility": "Accelovance", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Integris Family Care South", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73170", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "The Office Of Patricia Buchanan", "city": "Eugene", "state": "Oregon", "zip": "97404", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Cumberland Valley Endocrinology Center, Llc", "city": "Carlisle", "state": "Pennsylvania", "zip": "17015", "country": "United States", "geoPoint": {"lat": 40.20148, "lon": -77.18887}}, {"facility": "Fleetwood Clinical Research", "city": "Fleetwood", "state": "Pennsylvania", "zip": "19522", "country": "United States", "geoPoint": {"lat": 40.45398, "lon": -75.81798}}, {"facility": "Banksville Medical, Pc", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15216", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Biomedical Research Associates, Llc", "city": "Shippensburg", "state": "Pennsylvania", "zip": "17257", "country": "United States", "geoPoint": {"lat": 40.05065, "lon": -77.52026}}, {"facility": "Middle Tyger Family Medicine", "city": "Duncan", "state": "South Carolina", "zip": "29334", "country": "United States", "geoPoint": {"lat": 34.9379, "lon": -82.14511}}, {"facility": "Southeastern Research Assoc", "city": "Taylors", "state": "South Carolina", "zip": "29687", "country": "United States", "geoPoint": {"lat": 34.92039, "lon": -82.29623}}, {"facility": "Versoza & Ungab Internal Medicine Associates", "city": "Bartlett", "state": "Tennessee", "zip": "38134", "country": "United States", "geoPoint": {"lat": 35.20453, "lon": -89.87398}}, {"facility": "Collierville Medical Specialist", "city": "Collierville", "state": "Tennessee", "zip": "38017", "country": "United States", "geoPoint": {"lat": 35.04204, "lon": -89.66453}}, {"facility": "Holston Medical Group", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Med-South Research", "city": "Memphis", "state": "Tennessee", "zip": "38116", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Southwind Medical Specialist", "city": "Memphis", "state": "Tennessee", "zip": "38125", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Precision Family Medicine", "city": "Carrollton", "state": "Texas", "zip": "75010", "country": "United States", "geoPoint": {"lat": 32.95373, "lon": -96.89028}}, {"facility": "Alpha Therapy Research Center", "city": "Corpus Christi", "state": "Texas", "zip": "78411", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "Village Family Practice", "city": "Houston", "state": "Texas", "zip": "77024", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Texas Center For Drug Development, P.A.", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Abbott Clinical Research Group, Inc", "city": "San Antonio", "state": "Texas", "zip": "78224", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Taylor/Wade Medical", "city": "Bountiful", "state": "Utah", "zip": "84010", "country": "United States", "geoPoint": {"lat": 40.88939, "lon": -111.88077}}, {"facility": "Optimum Clinical Research", "city": "Salt Lake City", "state": "Utah", "zip": "84102", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Tidewater Integrated Medical Research", "city": "Virginia Beach", "state": "Virginia", "zip": "23451", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"facility": "Spokane Internal Medicine", "city": "Spokane", "state": "Washington", "zip": "99216", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Local Institution", "city": "Manipal", "state": "Karnataka", "zip": "576104", "country": "India"}, {"facility": "Local Institution", "city": "Kochi", "state": "Kerala", "zip": "682026", "country": "India", "geoPoint": {"lat": 9.93988, "lon": 76.26022}}, {"facility": "Local Institution", "city": "Attavar", "state": "Mangalore", "zip": "575001", "country": "India"}, {"facility": "Local Institution", "city": "Sarita Vihar", "state": "New Delhi", "zip": "110076", "country": "India"}, {"facility": "Local Institution", "city": "Bangalore", "zip": "560034", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Local Institution", "city": "Mumbai", "zip": "400007", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Local Institution", "city": "Mumbai", "zip": "400021", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Local Institution", "city": "Nagpur", "zip": "440012", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Local Institution", "city": "Moscov", "zip": "118089", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "115487", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Nizhniy Novgorod", "zip": "603126", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Local Institution", "city": "Saint Petersburg", "zip": "198013", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Saratov", "zip": "410018", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Local Institution", "city": "Saratov", "zip": "410054", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Local Institution", "city": "Smolensk", "zip": "214018", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Local Institution", "city": "St.Petersburg", "zip": "194156", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Volgograd", "zip": "400138", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Local Institution", "city": "Changhua", "zip": "500", "country": "Taiwan", "geoPoint": {"lat": 24.07327, "lon": 120.56276}}, {"facility": "Local Institution", "city": "Kaohsiung County", "zip": "833", "country": "Taiwan"}, {"facility": "Local Institution", "city": "Taichung City", "zip": "407", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Local Institution", "city": "Taichung", "zip": "402", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Local Institution", "city": "Taipei City", "zip": "114", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Local Institution", "city": "Tao-Yuan County", "zip": "333", "country": "Taiwan"}]}, "referencesModule": {"references": [{"pmid": "27402391", "type": "DERIVED", "citation": "Perl S, Cook W, Wei C, Iqbal N, Hirshberg B. Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. Diabetes Ther. 2016 Sep;7(3):527-35. doi: 10.1007/s13300-016-0184-9. Epub 2016 Jul 11."}, {"pmid": "27033025", "type": "DERIVED", "citation": "Bonora E, Bryzinski B, Hirshberg B, Cook W. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. Nutr Metab Cardiovasc Dis. 2016 May;26(5):374-9. doi: 10.1016/j.numecd.2015.11.004. Epub 2015 Dec 1."}, {"pmid": "22828124", "type": "DERIVED", "citation": "Frederich R, McNeill R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012 Jul 24;4(1):36. doi: 10.1186/1758-5996-4-36."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Saxagliptin 2.5 mg Once in the Morning (QAM)", "description": "The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily."}, {"id": "FG001", "title": "Saxagliptin 5 mg QAM", "description": "The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily."}, {"id": "FG002", "title": "Saxagliptin 2.5/5 mg QAM", "description": "The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM."}, {"id": "FG003", "title": "Saxagliptin 5 mg Once in the Evening (QPM)", "description": "The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily."}, {"id": "FG004", "title": "Placebo", "description": "The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "74"}, {"groupId": "FG001", "numSubjects": "74"}, {"groupId": "FG002", "numSubjects": "71"}, {"groupId": "FG003", "numSubjects": "72"}, {"groupId": "FG004", "numSubjects": "74"}]}, {"type": "Completed Study Without Being Rescued", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "35"}, {"groupId": "FG002", "numSubjects": "29"}, {"groupId": "FG003", "numSubjects": "27"}, {"groupId": "FG004", "numSubjects": "31"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "52"}, {"groupId": "FG002", "numSubjects": "44"}, {"groupId": "FG003", "numSubjects": "46"}, {"groupId": "FG004", "numSubjects": "48"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "27"}, {"groupId": "FG003", "numSubjects": "26"}, {"groupId": "FG004", "numSubjects": "26"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "6"}]}, {"type": "Withdrawal of Consent by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "5"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "6"}]}, {"type": "Poor/noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "4"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "Subject no longer meets study criteria", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Administrative reason by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin 2.5 mg Once in the Morning (QAM)", "description": "The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily."}, {"id": "BG001", "title": "Saxagliptin 5 mg QAM", "description": "The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily."}, {"id": "BG002", "title": "Saxagliptin 2.5/5 mg QAM", "description": "The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM."}, {"id": "BG003", "title": "Saxagliptin 5 mg Once in the Evening (QPM)", "description": "The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily."}, {"id": "BG004", "title": "Placebo", "description": "The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "71"}, {"groupId": "BG003", "value": "72"}, {"groupId": "BG004", "value": "74"}, {"groupId": "BG005", "value": "365"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.24", "spread": "10.44"}, {"groupId": "BG001", "value": "54.66", "spread": "9.71"}, {"groupId": "BG002", "value": "54.28", "spread": "10.93"}, {"groupId": "BG003", "value": "55.11", "spread": "10.35"}, {"groupId": "BG004", "value": "55.57", "spread": "10.32"}, {"groupId": "BG005", "value": "54.98", "spread": "10.31"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "34"}, {"groupId": "BG003", "value": "39"}, {"groupId": "BG004", "value": "39"}, {"groupId": "BG005", "value": "197"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "33"}, {"groupId": "BG004", "value": "35"}, {"groupId": "BG005", "value": "168"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1 (A1C) at Week 24", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement. If participant received rescue medication, measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg QAM", "description": "The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily."}, {"id": "OG001", "title": "Saxagliptin 5 mg QAM", "description": "The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily."}, {"id": "OG002", "title": "Saxagliptin 2.5/5 mg QAM", "description": "The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM."}, {"id": "OG003", "title": "Placebo", "description": "The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "69"}, {"groupId": "OG003", "value": "68"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.04", "spread": "0.105"}, {"groupId": "OG001", "value": "7.93", "spread": "0.106"}, {"groupId": "OG002", "value": "8.02", "spread": "0.131"}, {"groupId": "OG003", "value": "7.79", "spread": "0.112"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.30", "spread": "0.106"}, {"groupId": "OG001", "value": "7.27", "spread": "0.129"}, {"groupId": "OG002", "value": "7.37", "spread": "0.137"}, {"groupId": "OG003", "value": "7.57", "spread": "0.141"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.71", "spread": "0.103"}, {"groupId": "OG001", "value": "-0.66", "spread": "0.102"}, {"groupId": "OG002", "value": "-0.63", "spread": "0.102"}, {"groupId": "OG003", "value": "-0.26", "spread": "0.103"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg QPM", "description": "The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.88", "spread": "0.111"}, {"groupId": "OG001", "value": "7.79", "spread": "0.112"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.29", "spread": "0.124"}, {"groupId": "OG001", "value": "7.57", "spread": "0.141"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.61", "spread": "0.101"}, {"groupId": "OG001", "value": "-0.26", "spread": "0.103"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Mean change from baseline in FPG at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg Once in the Morning (QAM)", "description": "The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily."}, {"id": "OG001", "title": "Saxagliptin 5 mg QAM", "description": "The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily."}, {"id": "OG002", "title": "Saxagliptin 2.5/5 mg QAM", "description": "The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM."}, {"id": "OG003", "title": "Saxagliptin 5 mg Once in the Evening (QPM)", "description": "The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily."}, {"id": "OG004", "title": "Placebo", "description": "The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "71"}, {"groupId": "OG003", "value": "71"}, {"groupId": "OG004", "value": "71"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "156.6", "spread": "3.96"}, {"groupId": "OG001", "value": "162.2", "spread": "4.24"}, {"groupId": "OG002", "value": "170.6", "spread": "6.15"}, {"groupId": "OG003", "value": "159.6", "spread": "5.32"}, {"groupId": "OG004", "value": "158.6", "spread": "5.44"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "146.8", "spread": "3.79"}, {"groupId": "OG001", "value": "151.3", "spread": "5.88"}, {"groupId": "OG002", "value": "155.2", "spread": "5.88"}, {"groupId": "OG003", "value": "152.4", "spread": "5.88"}, {"groupId": "OG004", "value": "162.9", "spread": "6.28"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.4", "spread": "4.50"}, {"groupId": "OG001", "value": "-10.7", "spread": "4.46"}, {"groupId": "OG002", "value": "-12.5", "spread": "4.48"}, {"groupId": "OG003", "value": "-7.9", "spread": "4.46"}, {"groupId": "OG004", "value": "3.3", "spread": "4.46"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving A1C < 7% at Week 24", "description": "Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in the Week 24 LOCF analysis, participants must have had at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg Once in the Morning (QAM)", "description": "The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily."}, {"id": "OG001", "title": "Saxagliptin 5 mg QAM", "description": "The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily."}, {"id": "OG002", "title": "Saxagliptin 2.5/5 mg QAM", "description": "The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM."}, {"id": "OG003", "title": "Saxagliptin 5 mg Once in the Evening (QPM)", "description": "The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily."}, {"id": "OG004", "title": "Placebo", "description": "The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "69"}, {"groupId": "OG003", "value": "70"}, {"groupId": "OG004", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35.8"}, {"groupId": "OG001", "value": "44.9"}, {"groupId": "OG002", "value": "43.5"}, {"groupId": "OG003", "value": "38.6"}, {"groupId": "OG004", "value": "35.3"}]}]}]}, {"type": "SECONDARY", "title": "Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24", "description": "Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg*min/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg Once in the Morning (QAM)", "description": "The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily."}, {"id": "OG001", "title": "Saxagliptin 5 mg QAM", "description": "The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily."}, {"id": "OG002", "title": "Saxagliptin 2.5/5 mg QAM", "description": "The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM."}, {"id": "OG003", "title": "Saxagliptin 5 mg Once in the Evening (QPM)", "description": "The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily."}, {"id": "OG004", "title": "Placebo", "description": "The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "47"}, {"groupId": "OG003", "value": "43"}, {"groupId": "OG004", "value": "47"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "47432", "spread": "1496.6"}, {"groupId": "OG001", "value": "50417", "spread": "1561.5"}, {"groupId": "OG002", "value": "50032", "spread": "1684.7"}, {"groupId": "OG003", "value": "47078", "spread": "1941.9"}, {"groupId": "OG004", "value": "47640", "spread": "1759.7"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "39798", "spread": "1347.0"}, {"groupId": "OG001", "value": "41562", "spread": "1489.3"}, {"groupId": "OG002", "value": "41745", "spread": "1739.2"}, {"groupId": "OG003", "value": "41530", "spread": "1962.7"}, {"groupId": "OG004", "value": "44861", "spread": "1854.7"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8014", "spread": "1246.9"}, {"groupId": "OG001", "value": "-8218", "spread": "1249.1"}, {"groupId": "OG002", "value": "-7781", "spread": "1261.0"}, {"groupId": "OG003", "value": "-6048", "spread": "1318.2"}, {"groupId": "OG004", "value": "-3088", "spread": "1259.7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.", "seriousNumAffected": 5, "seriousNumAtRisk": 74, "otherNumAffected": 22, "otherNumAtRisk": 74}, {"id": "EG001", "title": "Saxagliptin 2.5/5 mg QAM", "description": "The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM.", "seriousNumAffected": 7, "seriousNumAtRisk": 71, "otherNumAffected": 30, "otherNumAtRisk": 71}, {"id": "EG002", "title": "Saxagliptin 2.5 mg QAM", "description": "The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.", "seriousNumAffected": 7, "seriousNumAtRisk": 74, "otherNumAffected": 32, "otherNumAtRisk": 74}, {"id": "EG003", "title": "Saxagliptin 5 mg QAM", "description": "The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.", "seriousNumAffected": 8, "seriousNumAtRisk": 74, "otherNumAffected": 33, "otherNumAtRisk": 74}, {"id": "EG004", "title": "Saxagliptin 5 mg QPM", "description": "The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.", "seriousNumAffected": 4, "seriousNumAtRisk": 72, "otherNumAffected": 29, "otherNumAtRisk": 72}], "seriousEvents": [{"term": "RETINAL DETACHMENT", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "ANGINA PECTORIS", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "ANGINA UNSTABLE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "ATRIAL FIBRILLATION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "COR PULMONALE ACUTE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "CORONARY ARTERY DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "ACUTE MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "ARTERIAL DISORDER", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "CHOLECYSTITIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "CHOLECYSTITIS ACUTE", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 72}]}, {"term": "TRANSIENT ISCHAEMIC ATTACK", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "RECTAL POLYP", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 72}]}, {"term": "ABDOMINAL PAIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "FOOD POISONING", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "GASTRITIS EROSIVE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 72}]}, {"term": "VERTIGO", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "CELLULITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "INFECTED BITES", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "PNEUMOCOCCAL SEPSIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "NEPHROLITHIASIS", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "CALCULUS URETERIC", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "HYPOGLYCAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "INTERTRIGO", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "OVERDOSE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 72}]}, {"term": "LIGAMENT RUPTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "FEMORAL NECK FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "SPINAL COMPRESSION FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "OSTEOARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "CHEST PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "UTERINE CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "PANCREATIC CARCINOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "HEPATIC CANCER METASTATIC", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}], "otherEvents": [{"term": "HYPERTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 72}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 72}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 72}]}, {"term": "DYSPEPSIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "RHINITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "SINUSITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 72}]}, {"term": "GASTROENTERITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 72}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 72}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 72}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 11, "numAtRisk": 72}]}, {"term": "JOINT INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 72}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 72}]}, {"term": "ARTHRALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 72}]}, {"term": "PAIN IN EXTREMITY", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 72}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 72}]}, {"term": "ASTHENIA", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 72}]}, {"term": "OEDEMA PERIPHERAL", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 71}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 72}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}